Clinical Trials
12 trialsNCT06756035 2026-06-04
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
Phase 1 Recruiting
NCT01064648 2026-05-29
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03228537 2026-05-29
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06477419 2026-05-28
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02959463 2026-05-27
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06051695 2026-05-26
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT04158141 2026-05-19
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
Phase 3 Terminated
NCT03007030 2026-05-15
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05568680 2026-05-12
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
Phase 1 Recruiting
NCT02399371 2026-05-08
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
Phase 2 Completed
NCT06251310 2026-05-08
SW-682 in Advanced Solid Tumors
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Recruiting
NCT03684486 2026-05-06
RehabKBP
University Hospital, Toulouse
Phase NA Terminated